Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.
Summary
This study identifies ciclopirox olamine as a direct, selective NLRP3 inflammasome inhibitor that binds the NACHT domain (Y381), reduces ATPase activity, and blocks oligomerization. CPX demonstrated therapeutic efficacy in murine sepsis, with additional benefits in colitis and metabolic models, and showed activity ex vivo in human cells.
Key Findings
- Ciclopirox selectively inhibited NLRP3 inflammasome activation without affecting AIM2, NLRC4, Pyrin, NLRP1, or NLRP6.
- CPX bound the NLRP3 NACHT domain at Y381, reduced ATPase activity, and blocked NLRP3 oligomerization and assembly.
- Therapeutic administration improved outcomes in mouse models of LPS-induced sepsis and was active ex vivo in human cells, including from gout patients.
Clinical Implications
Although preclinical, CPX could be rapidly advanced into early-phase trials for NLRP3-driven conditions including sepsis. Dosing, pharmacokinetics, and safety for systemic use require rigorous evaluation before clinical adoption.
Why It Matters
Provides a drug-repurposing route with a defined molecular mechanism to target a central inflammatory driver relevant to sepsis. The mechanistic specificity and in vivo efficacy substantially advance translational potential.
Limitations
- Evidence is preclinical; systemic dosing, pharmacokinetics, and safety of CPX for sepsis are not established
- Potential off-target effects and species differences in NLRP3 binding require further study
Future Directions
Perform dose-ranging, PK/PD, and safety studies for systemic CPX; validate efficacy in polymicrobial sepsis (e.g., CLP) and human primary immune cells; explore structure-guided optimization of NACHT-binding derivatives.
Study Information
- Study Type
- Basic/mechanistic study
- Research Domain
- Pathophysiology/Treatment
- Evidence Level
- V - Preclinical mechanistic experiments with murine models and ex vivo human cells
- Study Design
- OTHER